Professional Documents
Culture Documents
Abbreviations:
KOA = knee osteoarthritisRCTs =
randomized clinical trails
The datasets generated during and/or
analyzed during the current study are
publicly available.
This research was supported by the
National Key Research and
Development Program
(2019YFC1709900).
Go to:
References
[1] Hunter DJ, Bierma-Zeinstra S.
Osteoarthritis. Lancet. 2019;393:1745–
59. [PubMed] [Google Scholar]
[2] Woolf AD, Pfleger B. Burden of
major musculoskeletal conditions. Bull
World Health Organ. 2003;81:646–56.
[PMC free article] [PubMed] [Google
Scholar]
[3] Bijlsma JW, Berenbaum F, Lafeber
FP. Osteoarthritis: an update with
relevance for clinical practice. Lancet.
2011;377:2115–26. [PubMed] [Google
Scholar]
[4] Vos T, Flaxman AD, Naghavi M, et
al.. Years lived with disability (YLDs) for
1160 sequelae of 289 diseases and
injuries 1990-2010: a systematic
analysis for the Global Burden of
Disease Study 2010 [published
correction appears in Lancet. 2013 Feb
23;381(9867):628. AlMazroa,
Mohammad A [added]; Memish, Ziad A
[added]]. Lancet. 2012;380:2163–96.
[PMC free article] [PubMed] [Google
Scholar]
[5] Nüesch E, Dieppe P, Reichenbach S,
et al.. All cause and disease specific
mortality in patients with knee or hip
osteoarthritis: population based cohort
study. BMJ. 2011;342:d1165. Published
2011 Mar 8. [PMC free article]
[PubMed] [Google Scholar]
[6] Michael JW, Schlüter-Brust KU,
Eysel P. The epidemiology, etiology,
diagnosis, and treatment of
osteoarthritis of the knee [published
correction appears in Dtsch Arztebl Int.
2010 Apr;107(16):294]. Dtsch Arztebl
Int. 2010;107:152–62. [PMC free
article] [PubMed] [Google Scholar]
[7] Tang X, Wang S, Zhan S, et al.. The
prevalence of symptomatic knee
Osteoarthritis in China: results from
the China Health and retirement
longitudinal study. Arthritis Rheumatol
2016;68:648–53. [PubMed] [Google
Scholar]
[8] Cooper C, Chapurlat R, Al-Daghri N,
et al.. Safety of oral non-selective non-
steroidal anti-inflammatory drugs in
osteoarthritis: what does the literature
say? Drugs Aging. 2019;36(Suppl 1):15–
24. [PMC free article] [PubMed]
[Google Scholar]
2.6. Assessment of heterogeneity
I2 will be used for assessing statistical
heterogeneity. It is acknowledged that
I2 < 25% indicates negligible
heterogeneity, 25% < I2 < 50%
indicates mild heterogeneity, 50% < I2
< 75% moderate heterogeneity, and I2
≥ 75% high heterogeneity.